Literature DB >> 17587419

The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors.

Mie Hayashida1, Kuniaki Seyama, Yoshikazu Inoue, Keisaku Fujimoto, Keishi Kubo.   

Abstract

BACKGROUND AND
OBJECTIVE: To evaluate the characteristics and prognostic factors of Japanese patients with lymphangioleiomyomatosis (LAM).
METHODS: A nationwide survey to identify patients with LAM was conducted by questionnaire. Survival probability was estimated using the Kaplan-Meier method, and the prognostic factors were analysed by Cox regression.
RESULTS: Data were collected on 173 patients with pulmonary LAM. The major presenting features were pneumothorax (43%) and exertional dyspnoea (37%). The survival probabilities for patients presenting with exertional dyspnoea (Group A) were 85%, 60% and 47% after 5, 10 and 15 years, respectively, and for patients presenting with pneumothorax (Group B) were 95%, 89% and 89%, respectively. Although the age at symptom onset was higher among patients in Group A than in Group B, Cox regression revealed that the presenting feature was a prognostic factor independent of age at symptom onset (Group A/B hazard ratio = 5.732, P < 0.01). In the subgroup of patients whose initial FEV(1) was >1000 mL, or FEV(1)/FVC >40%, or %DL(CO) >40%, the rate of deterioration in these tests was greater in Group A than in Group B (P < 0.01 for FEV(1), P < 0.05 for FEV(1)/FVC and %DL(CO)).
CONCLUSIONS: There are two possible subgroups of LAM patients. One subgroup that presented with pneumothorax, had onset of symptoms at a younger age and a more favourable prognosis; the other presented with exertional dyspnoea, had onset of symptoms at an older age and a poorer prognosis.

Entities:  

Mesh:

Year:  2007        PMID: 17587419     DOI: 10.1111/j.1440-1843.2007.01101.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  32 in total

1.  Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function.

Authors:  Andrew M Courtwright; Bruno G Baldi; Pranav Kidambi; Ye Cui; Anthony M Lamattina; Julian A Villalba; Shefali Bagwe; Hilary J Goldberg; Ivan O Rosas; Elizabeth Petri Henske; Carlos R R Carvalho; Souheil El-Chemaly
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 2.  Feasibility of immunotherapy for lymphangioleiomyomatosis.

Authors:  Michele Carbone
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

Review 3.  Spontaneous pneumothorax in diffuse cystic lung diseases.

Authors:  Joseph Cooley; Yun Chor Gary Lee; Nishant Gupta
Journal:  Curr Opin Pulm Med       Date:  2017-07       Impact factor: 3.155

4.  The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.

Authors:  Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

5.  Lymphangioleiomyoma cells and lymphatic endothelial cells: expression of VEGFR-3 in lymphangioleiomyoma cell clusters.

Authors:  Kuniaki Seyama; Keiko Mitani; Toshio Kumasaka; Shiv K Gupta; Saji Oommen; Gang Liu; Jay H Ryu; Nicholas E Vlahakis
Journal:  Am J Pathol       Date:  2010-03-04       Impact factor: 4.307

Review 6.  Pulmonary manifestations in tuberous sclerosis complex.

Authors:  Nishant Gupta; Elizabeth P Henske
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-07-28       Impact factor: 3.908

7.  The NHLBI LAM Registry: Prognostic Physiologic and Radiologic Biomarkers Emerge From a 15-Year Prospective Longitudinal Analysis.

Authors:  Nishant Gupta; Hye-Seung Lee; Jay H Ryu; Angelo M Taveira-DaSilva; Gerald J Beck; Jar-Chi Lee; Kevin McCarthy; Geraldine A Finlay; Kevin K Brown; Stephen J Ruoss; Nilo A Avila; Joel Moss; Francis X McCormack
Journal:  Chest       Date:  2018-06-22       Impact factor: 9.410

8.  Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis.

Authors:  Riffat Meraj; Kathryn A Wikenheiser-Brokamp; Lisa R Young; Sue Byrnes; Francis X McCormack
Journal:  Front Med       Date:  2012-12-07       Impact factor: 4.592

9.  Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry.

Authors:  N Oprescu; F X McCormack; S Byrnes; B W Kinder
Journal:  Lung       Date:  2012-09-25       Impact factor: 2.584

Review 10.  Lymphatic involvement in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo M Taveira-Dasilva; Thomas N Darling; Joel Moss
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.